Evidence map›Paper›PMID 29813091›Full record

ArticlePloS one2018

Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension.

Ghaleb Khirfan, Vickram Tejwani, Xiaofeng Wang, Manshi Li, Joseph DiDonato, Raed A Dweik, Nicholas Smedira, Gustavo A Heresi

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ghaleb KhirfanDepartment of Internal Medicine, Medicine Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.ORCID 0000-0001-8506-4676
Vickram TejwaniDivision of Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Xiaofeng WangDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, United States of America.
Manshi LiDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, United States of America.
Joseph DiDonatoDepartment of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, Ohio, United States of America.
Raed A DweikDepartment of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Nicholas SmediraDepartment of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio, United States of America.
Gustavo A HeresiDepartment of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Cleveland Clinic · USJohns Hopkins Hospital · US

Funding

Insulin Resistance in Pulmonary Arterial HypertensionK23HL125697 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI HERESI DAVILA, GUSTAVO ADOLFO · 2015 to 2019
$834k
NHLBI NIH HHS K23 HL125697
6 · The paper itself

Abstract

backgroundHigh Density Lipoprotein Cholesterol (HDL-C) has various anti-inflammatory, anti-atherogenic, anti-oxidant and anti-coagulant properties that improve vascular function. The utility of HDL-C as a biomarker of severity and predictor of survival was described in patients with pulmonary arterial hypertension (PAH). No prior study has assessed the utility of HDL-C in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

objectivesWe aim to measure HDL-C levels in CTEPH patients and compare it to those in PAH patients and controls and determine HDL-C associations with markers of disease severity, hemodynamics and mortality in CTEPH.

methodsWe retrospectively included patients with CTEPH, identified from the Cleveland Clinic Pulmonary Hypertension Registry. All patients had right heart catheterization (RHC) and imaging studies consistent with CTEPH. We collected demographics, co-morbidities, baseline laboratory data including plasma HDL-C, six-minute walk test (6MWT), echocardiography and RHC. HDL-C levels were compared to a cohort of patients with cardiovascular risk factors and a previously published PAH cohort.

resultsHDL-C levels were available for 90 patients with CTEPH (age: 57.4±13.9 years; female 40%), 69 patients with PAH (age: 46.7±12.8 years; female 90%) and 254 control subjects (age: 56.7±13 years; female 48%). HDL-C levels in CTEPH patients were lower compared to controls and higher compared to PAH patients (median, IQR: CTEPH: 44, 34-57 mg/dl; PAH: 35.3, 29-39 mg/dl; Control: 49, 40-60 mg/dl; p < 0.01 for both pairwise comparisons). In CTEPH, higher HDL-C was associated with decreased prevalence of right ventricular dilation on echocardiography (p = 0.02). 57 patients with CTEPH underwent pulmonary thromboendarterectomy, higher HDL-C was associated with a larger decrement in postoperative pulmonary vascular resistance (PVR) (r = 0.37, p = 0.049). HDL-C was not associated with mortality or other markers of disease severity.

conclusionsHDL-C levels in CTEPH patients were lower compared to control subjects, but higher compared to PAH patients. Higher HDL-C in CTEPH was associated with less right ventricular dilation and greater decrement in postoperative PVR. These data suggest that HDL-C may be a useful marker of small vessel disease in CTEPH.

Indexed as

AdultAgedBiomarkersCardiac CatheterizationCholesterol, HDLEchocardiographyEndarterectomyFemaleHumansHypertension, PulmonaryMaleMiddle AgedPulmonary EmbolismRetrospective StudiesSeverity of Illness IndexWalk TestBiomarkersCholesterol, HDL

Identifiers

PMID29813091
PMCPMC5973565
OpenAlexW2805369554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.